Assignee
DYNAVAX TECH CORP
US·43 granted patents·14 pending applications·1,291 citations·filing 1999–2025
Top patents by PatentIndex Score
57 records- 0197US8003115B2Chimeric immunomodulatory compounds and methods of using the sameDYNAVAX TECH CORP·Filed 2007·Granted Aug 23, 2011·41 cites·6 claims
- 0297US7255868B2Chimeric immunomodulatory compounds and methods of using the same—IDYNAVAX TECH CORP·Filed 2002·Granted Aug 14, 2007·83 cites·25 claims
- 0396US7250403B2Biodegradable immunomodulatory formulations and methods for use thereofDYNAVAX TECH CORP·Filed 2001·Granted Jul 31, 2007·71 cites·53 claims
- 0496US7183111B2Immunomodulatory formulations and methods for use thereofDYNAVAX TECH CORP·Filed 2001·Granted Feb 27, 2007·76 cites·41 claims
- 0596US7129222B2Immunomodulatory formulations and methods for use thereofDYNAVAX TECH CORP·Filed 2001·Granted Oct 31, 2006·84 cites·11 claims
- 0696US6589940B1Immunostimulatory oligonucleotides, compositions thereof and methods of use thereofDYNAVAX TECH CORP·Filed 1999·Granted Jul 8, 2003·325 cites·50 claims
- 0795US9993495B2Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lungDYNAVAX TECH CORP·Filed 2016·Granted Jun 12, 2018·9 cites·35 claims
- 0895US8372413B2Immunomodulatory polynucleotides and methods of using the sameDYNAVAX TECH CORP·Filed 2007·Granted Feb 12, 2013·30 cites·22 claims
- 0995US7157437B2Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequencesDYNAVAX TECH CORP·Filed 2001·Granted Jan 2, 2007·53 cites·23 claims
- 1094US7223398B1Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereofDYNAVAX TECH CORP·Filed 2000·Granted May 29, 2007·55 cites·31 claims
- 1194US6562798B1Immunostimulatory oligonucleotides with modified bases and methods of use thereofDYNAVAX TECH CORP·Filed 1999·Granted May 13, 2003·186 cites·67 claims
- 1293US10722591B2Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereofDYNAVAX TECH CORP·Filed 2018·Granted Jul 28, 2020·7 cites·121 claims
- 1393US9422564B2Immunostimulatory sequence oligonucleotides and methods of using the sameDYNAVAX TECH CORP·Filed 2014·Granted Aug 23, 2016·15 cites·17 claims
- 1493US7718622B2Compositions comprising structurally stable conjugate moleculesDYNAVAX TECH CORP·Filed 2006·Granted May 18, 2010·18 cites·37 claims
- 1592US10196643B2Immunostimulatory sequence oligonucleotides and methods of using the sameDYNAVAX TECH CORP·Filed 2016·Granted Feb 5, 2019·8 cites·17 claims
- 1691US9868955B2Human toll-like receptor inhibitors and methods of use thereofDYNAVAX TECH CORP·Filed 2013·Granted Jan 16, 2018·11 cites·20 claims
- 1791US9028845B2Chimeric immunomodulatory compounds and methods of using the same-IVDYNAVAX TECH CORP·Filed 2013·Granted May 12, 2015·10 cites·9 claims
- 1891US7628990B2Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereofDYNAVAX TECH CORP·Filed 2006·Granted Dec 8, 2009·17 cites·27 claims
- 1990US11827641B2Toll-like receptor antagonist compounds and methods of useDYNAVAX TECH CORP·Filed 2022·Granted Nov 28, 2023·1 cites·25 claims
- 2090US7884083B2Immunomodulatory compositions, methods of making, and methods of use thereofDYNAVAX TECH CORP·Filed 2003·Granted Feb 8, 2011·31 cites·37 claims
- 2190US7785610B2Chimeric immunomodulatory compounds and methods of using the same—IIIDYNAVAX TECH CORP·Filed 2002·Granted Aug 31, 2010·39 cites·7 claims
- 2290US7745606B2Immunostimulatory sequence oligonucleotides and methods of using the sameDYNAVAX TECH CORP·Filed 2003·Granted Jun 29, 2010·39 cites·10 claims
- 2389US10618896B2Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereofDYNAVAX TECH CORP·Filed 2018·Granted Apr 14, 2020·4 cites·15 claims
- 2487US9228184B2Human toll-like receptor inhibitors and methods of use thereofDYNAVAX TECH CORP·Filed 2013·Granted Jan 5, 2016·10 cites·28 claims
- 2586US11370794B2Toll-like receptor antagonist compounds and methods of useDYNAVAX TECH CORP·Filed 2017·Granted Jun 28, 2022·3 cites·28 claims
- 2686US7479285B1Methods of modulating an immune response using immunostimulatory sequences and compositions for use thereinDYNAVAX TECH CORP·Filed 2000·Granted Jan 20, 2009·28 cites·27 claims
- 2784US9950064B2Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereofDYNAVAX TECH CORP·Filed 2016·Granted Apr 24, 2018·5 cites·24 claims
- 2882US7625872B2Branched immunomodulatory compounds and methods of using the sameDYNAVAX TECH CORP·Filed 2003·Granted Dec 1, 2009·15 cites·2 claims
- 2981US11124510B2Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereofDYNAVAX TECH CORP·Filed 2020·Granted Sep 21, 2021·1 cites·21 claims
- 3079US12378255B2Toll-like receptor antagonist compounds and methods of useDYNAVAX TECH CORP·Filed 2023·Granted Aug 5, 2025·0 cites·17 claims
- 3179US2024368155A1Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereofDYNAVAX TECH CORP·Filed 2024·Application pending·0 cites
- 3277US10111899B2Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lungDYNAVAX TECH CORP·Filed 2018·Granted Oct 30, 2018·2 cites·21 claims
- 3374US7727712B2Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequencesDYNAVAX TECH CORP·Filed 2003·Granted Jun 1, 2010·12 cites·5 claims
- 3473US11981670B2Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereofDYNAVAX TECH CORP·Filed 2021·Granted May 14, 2024·0 cites·30 claims
- 3572US9884110B2Methods and compositions for eliciting an immune response against hepatitis B virusDYNAVAX TECH CORP·Filed 2016·Granted Feb 6, 2018·1 cites·14 claims
- 3671US10369168B2Administration of polynucleotide toll-like receptor 9 agonists for treating cancerDYNAVAX TECH CORP·Filed 2018·Granted Aug 6, 2019·0 cites·23 claims
- 3771US9347064B2Methods of treatment using TLR7 and/or TLR9 inhibitorsDYNAVAX TECH CORP·Filed 2014·Granted May 24, 2016·1 cites·19 claims
- 3869US12364745B2Immunogenicity of a CpG-adjuvanted recombinant plague vaccineDYNAVAX TECH CORP·Filed 2023·Granted Jul 22, 2025·0 cites·15 claims
- 3964US2025163105A1Immunogenicity of a cpg-adjuvanted herpes zoster vaccineDYNAVAX TECH CORP·Filed 2022·Application pending·0 cites
- 4061US2025360190A1Immunogenicity of a cpg-adjuvanted recombinant plague vaccineDYNAVAX TECH CORP·Filed 2025·Application pending·0 cites
- 4160US10350290B2Linear chimeric compounds and methods of use thereofDYNAVAX TECH CORP·Filed 2018·Granted Jul 16, 2019·0 cites·18 claims
- 4258US2015297737A1Chimeric immunomodulatory compounds and methods of using the same-ivDYNAVAX TECH CORP·Filed 2015·Application pending·0 cites
- 4357US10548975B2Branched chimeric compounds, and methods of use thereofDYNAVAX TECH CORP·Filed 2018·Granted Feb 4, 2020·0 cites·22 claims
- 4457US2023110516A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 4556US9333254B2Long term disease modification using immunostimulatory oligonucleotidesDYNAVAX TECH CORP·Filed 2014·Granted May 10, 2016·0 cites·18 claims
- 4654US2010183666A1Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequencesDYNAVAX TECH CORP·Filed 2010·Application pending·0 cites
- 4754US2023092650A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
- 4853US2015050296A1Methods and compositions for inhibition of innate immune responses and autoimmunityDYNAVAX TECH CORP·Filed 2014·Application pending·0 cites
- 4951US10314907B2Methods and compositions for eliciting an immune response against hepatitis B virusDYNAVAX TECH CORP·Filed 2018·Granted Jun 11, 2019·0 cites·11 claims
- 5051US2023218740A1Coronavirus vaccines comprising a tlr9 agonistDYNAVAX TECH CORP·Filed 2021·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DYNAVAX TECH CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →